Welcome to our dedicated page for Indaptus Therapeutics SEC filings (Ticker: INDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Indaptus Therapeutics, Inc. (Nasdaq: INDP) SEC filings page on Stock Titan provides structured access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology issuer incorporated in Delaware and listed on the Nasdaq Capital Market, Indaptus uses its SEC reports to describe the development of its Decoy bacterial immunotherapy platform, its clinical programs, and its financing and corporate activities.
Through Forms 10-K and 10-Q, investors can review detailed discussions of Indaptus’ business, including its focus on Decoy20 and related product candidates for cancer and viral infections, pre-clinical data summaries, risk factors, and management’s analysis of research and development and general and administrative expenses. Current reports on Form 8-K capture material events such as the launch and progression of the INDP-D101 clinical trial, reverse stock split implementation, private placements of convertible promissory notes and warrants, standby equity purchase agreements, preferred stock financings, and changes to the board of directors and executive leadership.
Registration statements on Form S-1 and amendments (S-1/A) outline the terms of securities offerings, including common stock, pre-funded warrants, common warrants and placement agent warrants, as well as estimated offering expenses and recent sales of unregistered securities. These filings also confirm Indaptus’ status as a smaller reporting company and non-accelerated filer and provide information on its incorporation and principal executive offices.
On Stock Titan, users can access these filings alongside AI-powered summaries that highlight key points such as capital structure changes, potential dilution from convertible instruments and warrants, and the implications of preferred stock transactions. The platform also surfaces insider-related disclosures and board changes reported in 8-Ks, helping readers quickly identify governance developments. Real-time updates from EDGAR ensure that new Indaptus filings, from quarterly earnings reports to material event disclosures, are added promptly, while AI-generated explanations help interpret complex prospectus language, financing terms and clinical program descriptions within the filings.
Indaptus Therapeutics, Inc. (CIK 0001857044) filed a Form D notice with the SEC to report a new exempt offering of securities. The biotechnology company, incorporated in Delaware in 2021 and operating from 3 Columbus Circle, New York, is claiming the Rule 506(c) exemption, which allows general solicitation provided that all purchasers are accredited investors.
Offering details:
- Date of first sale: 12 June 2025
- Securities offered: (i) Options, warrants, or other rights to acquire another security and (ii) the underlying securities issuable upon exercise of those rights
- Minimum investment: $0 USD, indicating flexibility for investor entry size
- Offering duration: The issuer does not expect the offering to last more than one year
- Issuer size: The company elected “Decline to Disclose” for both revenue and asset ranges
Intermediary & solicitation: Paulson Investment Company, LLC (CRD 000005670) is identified as the broker-dealer. Solicitation will occur in multiple U.S. states (e.g., CA, CO, FL) and in foreign jurisdictions.
Management & directors: The filing lists key executives and directors, including CEO Jeffrey A. Meckler, CFO Nir Sassi, and several directors such as Roger J. Pomerantz and Hila Karah. No promoters are designated.
Other disclosures: • The offering is not tied to a business-combination transaction.
• No sales compensation recipients beyond Paulson Investment Company are disclosed.
• The issuer is categorised under the “Pharmaceuticals” industry segment.
Information gaps: Items concerning total amount offered, sold, and remaining are not present in the excerpt, limiting visibility into potential dilution and capital inflow.